$10.81
10.36% today
Nasdaq, Apr 04, 08:46 pm CET
ISIN
US04280A1007
Symbol
ARWR

Arrowhead Pharmaceuticals, Inc. Stock price

$12.06
-5.65 31.90% 1M
-6.79 36.02% 6M
-6.74 35.85% YTD
-14.42 54.46% 1Y
-38.55 76.17% 3Y
-14.06 53.83% 5Y
+4.46 58.68% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.63 4.96%
ISIN
US04280A1007
Symbol
ARWR
Sector
Industry

Key metrics

Market capitalization $1.66b
Enterprise Value $1.98b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 791.46
P/S ratio (TTM) P/S ratio 662.42
P/B ratio (TTM) P/B ratio 28.80
Revenue growth (TTM) Revenue growth -98.62%
Revenue (TTM) Revenue $2.50m
EBIT (operating result TTM) EBIT $-625.95m
Free Cash Flow (TTM) Free Cash Flow $-576.61m
Cash position $552.94m
EPS (TTM) EPS $-5.15
P/E forward negative
P/S forward 4.90
EV/Sales forward 5.85
Short interest 9.83%
Show more

Is Arrowhead Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Arrowhead Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

10x Buy
67%
5x Hold
33%

Analyst Opinions

15 Analysts have issued a Arrowhead Pharmaceuticals, Inc. forecast:

Buy
67%
Hold
33%

Financial data from Arrowhead Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2.50 2.50
99% 99%
100%
- Direct Costs 20 20
39% 39%
783%
-17 -17
110% 110%
-683%
- Selling and Administrative Expenses 80 80
1% 1%
3,218%
- Research and Development Expense 509 509
36% 36%
20,354%
-606 -606
113% 113%
-24,255%
- Depreciation and Amortization 20 20
39% 39%
783%
EBIT (Operating Income) EBIT -626 -626
109% 109%
-25,038%
Net Profit -640 -640
116% 116%
-25,588%

In millions USD.

Don't miss a Thing! We will send you all news about Arrowhead Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Arrowhead Pharmaceuticals, Inc. Stock News

Positive
Seeking Alpha
14 days ago
Arrowhead Pharmaceuticals, Inc. has streamlined its focus, now boasting 19 clinical programs, including 4 phase 3 trials and 4 phase 2 trials. Plozasiran shows superior results in triglyceride reduction and dosing frequency compared to its main competitor, Olezarsen, with a pivotal PDUFA date on November 18. ARWR's strong financial position is bolstered by a recent deal with Sarepta, extending ...
Neutral
Business Wire
25 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company's investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to p...
Neutral
Business Wire
29 days ago
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weig...
More Arrowhead Pharmaceuticals, Inc. News

Company Profile

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Head office United States
CEO Christopher Anzalone
Employees 609
Founded 1989
Website www.arrowheadpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today